Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Accumulated Expenses (2016 - 2026)

Protara Therapeutics' Accumulated Expenses history spans 14 years, with the latest figure at $3.6 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 2.52% to $3.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Mar 2026, up 2.52% year-over-year, with the annual reading at $3.3 million for FY2025, 19.23% up from the prior year.
  • Accumulated Expenses came in at $3.6 million for Q1 2026, up from $3.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.6 million in Q1 2026 to a low of $936000.0 in Q2 2023.
  • The 5-year median for Accumulated Expenses is $2.4 million (2022), against an average of $2.4 million.
  • Year-over-year, Accumulated Expenses skyrocketed 220.09% in 2022 and then crashed 57.76% in 2023.
  • Protara Therapeutics' Accumulated Expenses stood at $3.2 million in 2022, then decreased by 15.6% to $2.7 million in 2023, then increased by 0.29% to $2.7 million in 2024, then increased by 19.23% to $3.3 million in 2025, then increased by 11.02% to $3.6 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Accumulated Expenses are $3.6 million (Q1 2026), $3.3 million (Q4 2025), and $1.6 million (Q3 2025).